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ABSTRACT
Disturbances of lipid metabolism are frequently en­
countered after renal transplantation and have been  
ascribed to the use of cyclosporine (CsA) and corti­
costeroids, but the individual contribution of each  of 
these drugs remains uncertain. The Individual effects 
of CsA and prednisone (Pred) on serum lipid and  
(apo)lipoprotein levels were com pared  in a  prospec­
tive randomized trial. All patients received CsA and  
Pred during the first 3 months after transplantation. 
Subsequently, they were allocated to either with­
drawal of Pred or conversion from CsA to azathioprine 
(Aza). Serum lipids and (apo)lipoproteins, including 
lipoprotein(a) (Lp(a)), were measured at regular in­
tervals during the first year after renal transplantation. 
Analysis of variance for repeated measures of the first 
year results showed higher values for serum triglycer­
ides (P <  0.001) and lower high-density lipoprotein 
(HDL) cholesterol levels (P <  0.05) in the CsA m ono­
therapy group (N = 59) as com pared with the Aza- 
Pred group (N = 63). At 1 yr after transplantation, 
CsA-treated patients had significantly higher Lp(a) 
levels (CsA: median, 105 (interquartile range 42 to 
340) mg/L; Aza-Pred: 46 (25 to 176) mg/L; P <  0.05). 
The withdrawal of Pred in the CsA group resulted in a  
large fall In HDL cholesterol (27 ±  30% at 5 months 
after transplantation) and an increase in triglycerides 
(49 ±  73% at 6 months). A reversion of these changes  
was observed in patients who were retreated with 
Pred. Multiple linear regression analysis showed an  
independent correlation between the use of Pred and
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HDL cholesterol level, whereas the use of CsA was 
independently associated with the concentration of 
Lp(a). The results indicate that with respect to risk for 
hyperlipidemia after renal transplantation, Aza-Pred 
treatment m ay be preferred ab o ve  CsA m ono­
therapy. These data  do not support the general belief 
that the withdrawal of steroids in CsA-treated patients 
improves the serum lipid and lipoprotein profile.
Key words: Serum cholesterol, lipoprotein (a), hyperlipidemia, 
atherosclerosis, renal transplantation
A therosclerosis is a major cause of morbidity and mortality after renal transplantation. One of the main risk factors for atherosclerosis is hyperlipid­
emia, and many studies have demonstrated that hy­
perlipidemia is frequently encountered in renal trans­
plant recipients (1). Elevated levels of serum total 
cholesterol, low-density lipoprotein cholesterol (LDL- 
C), and triglycerides (TG) are frequently observed (1- 
3). High-density lipoprotein cholesterol (HDL-C) levels 
have been variously reported as high, normal, or low* 
In recent years, elevated lipoprotein(a) [Lp(a)J concen­
trations have been reported in renal transplant pa­
tients treated with cyclosporine (CsA) (4). In addition 
to other factors, there is strong evidence for a patho­
genetic role of immunosuppressive drugs in post­
transplant hyperlipidemia. The adverse effects of cor­
ticosteroids on serum cholesterol and TG levels are 
well es tablished (2,5,6). The withdrawal of prednisone 
(Pred) in patients on CsA and azathioprine (Aza) led to 
significant decreases in total cholesterol levels (6-8). 
Numerous studies documented that treatment with 
CsA, alone or in combination with steroids, was asso­
ciated with increased levels of total and LDL-C and 
serum TG (6,9-12), although there are also studies in 
which these effects of CsA could not be demonstrated 
(13,14). The individual contribution of either drug to 
disturbances in lipid metabolism as well as their 
distinct effects on the various lipoprotein subclasses 
are not clear.
To clarify this issue, we measured serum lipids and 
lipoproteins in patients who participated in a random­
ized prospective trial comparing CsA monotherapy 
with the combination of Aza and Pred from 3 months 
after renal transplantation. Because Aza is not known 
to influence lipid metabolism, this actually meant a 
comparison of the effects of CsA and Pred. In addition 
to m ost of the previous studies on this subject, we also 
measured apolipoprotein (apo) A-I, apo B, and Lp(a). 
Apo A-I and apo B are the major protein components
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within high density lipoprotein (HDL) and low density 
lipoprotein (LDL), respectively. Lp(a) resembles LDL 
but has an additional apolipoprotein [apo(a)] that is 
structurally homologous to plasminogen. In epidemi­
ologic studies, apo B (15) and Lp(a) (16) were positively 
and apo A-I (15) was negatively associated with the 
risk for atherosclerotic cardiovascular disease. Be­
cause the initial treatment in all of our study patients 
consisted of CsA and Pred, the design of the trial also 
allowed the examination of the changes in lipid and 
apolipoproteins occurring after the withdrawal of Pred 
in CsA-treated patients, which we expected to be 
beneficial.
PATIENTS AND METHODS 
Patient Population
All patients underwent a first or second cadaveric renal 
transplantation at our institution. Postoperatively, they were 
treated with CsA and Pred for 3 months. Afterwards, they 
volunteered to participate in a randomized prospective trial, 
comparing CsA monotherapy (JV = 64) with the combination 
therapy of Aza and Pred (JV -  63). Two patients with diabetes 
mellitus (both in CsA group) were excluded from this analy­
sis, and another three patients in the CsA group could not be 
evaluated because of lacking data. The remaining 122 pa­
tients made up the study population.
Study Protocol
CsA was given iv (3 m g/kg per day) for the first 3 days 
postoperatively, followed by 12 mg/kg per day in two divided 
oral doses during the first month, gradually reduced to 4 
m g/kg per day at 3 months after transplantation. The dosage 
was adjusted to maintain CsA trough blood levels between 
200 and 400 ng/mL. Prednisolone was given at a dose of 100 
m g/day iv during the first 2 days postoperatively, followed by 
an oral Pred dosage of 25 mg/day during the remainder of 
the first month and 20 mg/day during the second and third 
months after transplantation, In patients who were random­
ized to receive CsA monotherapy, CsA was continued in the 
same dosage with adjustments to reach trough blood levels 
between 100 and 200 ng/mL. The Pred dosage was reduced 
by 5 m g/day every 2 wk, resulting in CsA monotherapy after
6 wk. In patients allocated to Aza-Pred therapy, CsA was 
replaced without overlap by Aza in a dosage of 3 mg/kg. Their 
Pred dosage was temporarily increased from 20 to 25 mg/day 
and reduced by 5 m g/day every 2 wk until a maintenance 
dose of 10 m g/day was reached. In the CsA group, Pred was 
restarted if more than one acute rejection or chronic vascular 
rejection occurred after randomization. The same conditions 
led to the replacement of Aza by CsA in the Aza-Pred group. 
In case of severe and persistent side effects, attributable to 
one of the drugs, patients changed over to the alternative 
treatment regimen,
During the first 3 months after transplantation, acute 
rejection episodes were treated with methylprednisolone (1 g 
iv on three consecutive days) or antihymocyte globulin (ATG; 
RTVM Bilthoven, The Netherlands; 200 mg iv on alternate 
days for 10 days). An oral course of high-dose Pred (initial 
dosage 200 m g/day tapering to 25 mg/day in 12 days) was 
given after the failure of one or both of these treatments.
From 3 months after transplantation (i.e., after randomiza­
tion), acute rejections were primarily treated with ATG in all 
cases. High-dose Pred courses were given in case of the
failure of ATG, bone marrow suppression, or previous treat­
ment with ATG for rejection.
Hypertension, defined as diastolic blood pressure above 95 
mm Hg on three consecutive occasions, was treated in a 
standard way with a /3-blocker (atenolol), followed by the 
successive addition of a calcium antagonist (nifedipine) and a 
diuretic (chlortalidone) when necessary. None of the patients 
were treated with lipid-lowering drugs. There were no dietary 
recommendations given except for caloric restriction in pa­
tients with a large weight gain after transplantation.
Blood samples for the measurement of serum total choles­
terol, HDL-C, TG, and plasma glucose were collected after an 
overnight fast at 2 and 3 months (baseline values), as well as 
at 5, 6, 9, and 12 months after transplantation. Apo A-I and 
apo B were measured in the samples obtained at 3, 6, and 12 
months, whereas Lp(a) was measured at 3 and 12 months 
after transplantation. In the samples obtained at 12 months, 
very low-density lipoprotein (VLDL) cholesterol and TG were 
determined.
Body weight and blood pressure, as well as results from 
routine clinical chemistry, were recorded at regular intervals 
as part of the usual posttransplant patient evaluation. Body 
mass index was calculated as weight in kilograms divided by 
the square of the height in meters. Creatinine clearance was 
estimated with the formula given by Cockcroft and Gault
(17). Proteinuria was defined as a urinary protein concentra­
tion of more than 0.1 g/L  (24-h urinary protein excretion was 
not measured routinely). The study was approved by the 
Hospital Ethics Committee, and all patients gave written 
informed consent.
Analytical Procedures
Cholesterol and TG were measured by enzymatic methods 
(CHOD-PAP cholesterol reagent; Boehringer-Mannheim, 
Mannheim, Germany, and SERA-PAK TG, Miles, Italy with a 
centrifugal analyzer (Multistat III; Instrumentation Labora­
tory Inc., Lexington, MA). HDL-C was measured as described
(18). LDL-C was calculated by the Friedewald formula (19). 
VLDL was isolated by ultracentrifugation at d = 1.006 g/mL 
with a Kontron TFT 45.6 rotor (Kontran Instruments AG, 
Miles, Italy) for 16 h at 168,000 X g at 14°C in a Beckman 
L7-55 ultracentrifuge (Beckman Instruments Inc., Palo Alto, 
CA) (20). Serum sam ples to be analyzed for apolipoproteins 
were stored at -  20°C constant temperature until assay. Apo 
A-I and apo B were measured by immunonephelometry (21), 
and the results were International Federation of Clinical 
Chemistry (IFCC) standardized by recalculation on the basis 
of an exchange of 40 serum samples with Dr. S. Marcovina 
(North-West Lipid Research Laboratory, Seattle, WA), who 
uses a radioimmunoassay. Lp(a) was measured by a com­
mercial immunoradiometric assay [apo(a) IRMA; Pharmacia, 
Uppsala, Sweden], Accuracy was confirmed by analyzing the 
human Lp(a) reference standard no. 4395006, provided by 
Immuno GMBH (Vienna, Austria).
Serum creatinine and glucose levels were measured by 
standard techniques. The urine dipstick was used as a 
screening test for proteinuria. In samples with a positive 
result, the protein concentration was measured by a colori­
metric assay. Whole-blood CsA levels were measured with a 
fluorescence polarization immunoassay (Abbott Laborato­
ries, North Chicago, IL), initially with polyclonal antibodies 
directed against the parent molecule of CsA and some of its 
metabolites. The majority of blood levels was measured with 
a modified kit, with monoclonal antibodies against the CsA 
parent molecule without cross-reactivity. A conversion factor
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of 0.5 was used to adjust the initial values to those currently 
measured.
Statistical Analysis
All data were analyzed with the SAS system (SAS Institute 
Inc., Cary, NC). Data are given as means ± standard devia­
tions, unless stated otherwise. The logarithmic conversion of 
Lp(a) was performed to normalize the distribution. Compar­
ison of the changes after randomization between both treat­
ment groups was performed by analysis of variance for 
repeated measurements. Within-group comparisons and be­
tween-group comparisons at different times were carried out 
with paired or unpaired t tests. Proportions were compared 
with x2, analysis. Simple correlations within each treatment 
group were assessed by calculating Spearman’s correlation 
coefficient. Multiple linear regression analysis was used to 
examine the relative independent contributions of the use of 
CsA and Pred, as well as of several other clinical variables, to 
lipid levels at 1 yr after transplantation. A P value of less than 
0.05 was considered statistically significant. No correction 
for the comparison of multiple outcomes was applied.
RESULTS
Between 3 and 12 months after transplantation, one 
patient died in each treatment group (CsA, 4 months; 
Aza-Pred, 6 months after transplantation). In addi­
tion, graft loss occurred once in each group (CsA, 6 
months; Aza-Pred, 7 months after transplantation). 
The results obtained until the time of death or graft 
loss were included for analysis. In 37 patients, the 
initially assigned treatment had to be changed for a 
variety of reasons. Pred was added to CsA in eight 
patients because of the occurrence of more than one 
acute rejection or chronic rejection after steroid with­
drawal (one of these patients received triple therapy). 
In another six patients, steroid withdrawal was not 
completed for a variety of reasons. CsA was replaced 
by Aza-Pred in nine cases, all but once because of 
CsA-induced renal dysfunction (in one of these pa­
tients, CsA was substituted for Aza again, with the 
continuation of Pred). In two patients, Aza was re­
placed by CsA because they had a second acute 
rejection episode after prior conversion from CsA to 
Aza. Bone marrow depression and liver function d is­
turbances prompted switching from Aza to CsA in 
eight (in one of these temporarily) and four additional 
patients, respectively. Seven of the latter 12 patients 
were off Pred at 1 yr after transplantation. To deter­
mine the clinical effect of the two therapeutic ap­
proaches on lipid metabolism and cardiovascular risk, 
the data of all patients were analyzed on an intention- 
to-treat basis.
Intention-To-Treat Analysis
The demographic and clinical characteristics of the 
patients are shown in Table 1. There were no differ­
ences in these parameters between both groups. The 
values for serum lipids and (apo)lipoproteins m ea­
sured at 3, 6, and 12 months after transplantation are 
given in Table 2. In the CsA monotherapy group» total 
cholesterol and LDL-C did not change between 3 and
TABLE i. Characteristics of patients assigned to 
treatment with CsA m onotherapy or com bination  
therapy of Aza and  Pred from 3 months after renal 
transplantation0
Parameter CsA (N = 59)
Aza-Pred
(N = 63)
Sex (M/F) 38/21 41/22
Age (yr) 42 ± 12 42 ±  14
First/second transplantation 4 8 /n 53/10
Body mass index (kg/m 2) 23.7 ± 3.2 24.3 ±  3.9
Creatinine clearance 57 ± 18 56 ±  19
(mL/min)
Patients with proteinuria 8 (14%) 10 (16%)
Patients using antihypertensive 45 (76%) 47 (75%)
drugs
a Data at 3 months after transplantation,
12 months after transplantation; however, the con­
centration of HDL-C decreased considerably, with a 
maximal reduction of 27 ± 30% at 5 months after 
transplantation, whereas TG levels increased signifi­
cantly (maximal change of 49 ± 73% at 6 months). In 
the Aza-Pred group, there was also a significant de­
crease of the serum level of HDL-C ( -1 3  ± 25% at 6 
months). Analysis of variance showed that the 
changes after randomization differed significantly be­
tween both groups for HDL-C (a larger decrease in the 
CsA group; P < 0.05), for TG (an increase in the CsA 
group versus no change in the Aza-Pred grotip; P < 
0,001), and for the ratio of total cholesterol to HDL-C 
(a larger increase in the CsA group; P <  0.01). At 1 yr 
after transplantation, VLDL cholesterol was higher in 
the CsA group (CsA, 1.15 ± 0 .82 mmol/L; Aza-Pred, 
0.68 ± 0 .42 mmol/L; P <  0.01) as was the ratio of 
cholesterol to TG in the VLDL fraction (CsA, 0.76 ± 
0,21; Aza-Pred, 0.61 ± 0.15; P <  0.001). The concen­
tration of apo A-I was highly correlated with that of 
HDL-C (Æ = 0,72, 0.69, and 0.72 at 3, 6, and 12 
months; P < 0.001). Likewise, the level of apo B 
showed a strong correlation with that of LDL-C (R = 
0.82, 0.80, and 0 .64 at 3, 6, and 12 months; P <
0.001). Consequently, significant decreases in apo A-I 
were observed in both groups. Lp(a) concentration 
increased in the CsA monotherapy group and did not 
change after replacing Csa-Pred by Aza-Pred, result­
ing in a significant difference between both treatment 
groups at 1 yr after transplantation.
Table 3 summarizes the values of other clinical and 
laboratory parameters that could have influenced li­
poprotein metabolism. As expected, Aza-Pred-treated 
patients had higher creatinine clearances. Except for 
a negative correlation between creatinine clearance 
and apo A-I at 12 months after transplantation in the 
Aza-Pred group (R  = —0.28; P <  0.05), there were no 
significant correlations between creatinine clearance 
and lipid or (apo)lipoprotein levels at 6 or 12 m onths in  
either group. Proteinuria was more frequent in the 
Aza-Pred group at 6 months after transplantation. A
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TABLE 2. Lipid and  (apo)lipoprotein concentrations at 3, 6, and 12 months after renal transplantation in 
patients assigned to treatment with CsA monotherapy or with Aza-Pred
Parameter
CsA Aza-Pred
3 months 6 months 12 months 3 months 6 months 12 months
Serum cholesterol (mmol/L) 
Serum TG (mmol/L)
LD L-C hoi estero 1 (mmol/L) 
HDL-C (mmol/L)
Total/HDL-C 
apol A-l (mg/L) 
apol B (mg/L)
Lp(a) (mg/L)f
6.31 ±  1.63 
1.91 ±0.97
4.23 ±  1.51
1.31 ± 0.38
5.23 ±  2.05 
1,538 ± 325 
1,295 ± 399 
61 (25-168)
6.19 ± 1.40 
2.53 ± 1.42° 
4.12 ± 1.16 
1.01 ±0,34° 
6.82 ± 2.78a 
1,350 ± 328° 
1,314 ±347
6.28 ±  1.86 
2.37 ± 1.29° 
4.22 ±  1.67 
1.06 ± 0.38a 
6.72 ±  3.33° 
1,426 ± 326 
1,386 ±  409° 
105 (42-340)°
6.14 ±  1.33 
2.03 ±  0.94 
3.97 ±  1.08 
1.32 ±  0.48 
5.11 ±  1.82 
1,477 ±  271 
1,228 ±  332 
50 (25-244)
5.85 ± 1.31 
1.90 ± 0.99b 
4.02 ± 1.23 
1.13 ± 0«45a 
5.69 ± 1.90a,d 
1,398 ± 285 
1,257 ± 336
5.91 ± 1.43 
1.78 ±0.03b 
4.04 ± 1.30 
1.12 ± 0.37c 
5.73 ± 2.09° 
1,378 ± 232®
1,247 ± 338 
46 (25-176)d
a P < 0,001 for difference versus 3 months. 
b P < 0.01 for difference with CsA group. 
c P <  0.01 for difference versus 3 months, 
d P < 0.05 for difference with CsA group. 
e P < 0.05 for difference versus 3 months. 
f Given as median with Interquartile range-
TABLE 3. Clinical and  biochem ical parameters a t3 ( 6, and 12 months after renal transplantation in patients 
assigned to treatment with CsA monotherapy or with Aza-Pred
Parameter
CsA Aza-Pred
3 months 6 months 12 months 3 months 6 months 12 months
Weight (kg) 70 ± 11 72 ±  12 74 ±  13 70 ± 12 72 ± 13 73 ± 13
Creatinine clearance (mL/min) 57 ± 18 54 ± 15 54 ± 18 56 ± 18 65 ± 21° 67 ± 20b
Plasma glucose (mmol/L) 4.9 ±  1.0 5.0 ±  0.7 5.1 ± 0.7 5.8 ± 2.8C 5.1 ±  1.1 5.2 ± 1.4
Patients with proteinuria (%) 14 14 22 16 32° 27
Patients using a /3-blocker (%) 76 76 64 75 62 62
Patients using a calcium antagonist (%) 48 39 41 33 27 32
Patients using a diuretic (%) 5 3 12 5 6 10
CsA trough level (ng/mL) 220 ± 82 197 ± 87 177 ± 50 244 ± 124
a P < 0.01 for difference with CsA group, 
b P <  0.001 for difference with CsA group. 
c P < 0.05 for difference with CsA group,
comparison of patients with and without proteinuria 
revealed a difference for LDL-C at 12 months in the 
CsA group (5.23 ± 2.72 versus 3.97 ± 1 . 8  
P < 0.05). A significant correlation between changes in 
creatinine clearance or urinary protein excretion on 
the one hand and changes in lipid or (apo)lipoprotein 
levels on the other hand was only observed in the CsA 
group for the change in creatinine clearance between
3 and 6 months and the concurrent change in TG (JR = 
-0 .3 2 ; P < 0.05). Body weight increased to the same 
extent in both treatment groups. Although plasma 
glucose was slightly higher in the CsA group at 3 
months, there were no significant differences in 
plasma glucose after randomization. The use of the 
different classes of antihypertensive drugs was com­
parable. CsA blood levels tended to decline over time 
and showed no significant correlation with lipid or 
(apo)lipoprotein levels at 3, 6, or 12 months after 
transplantation. The number of acute rejection epi­
sodes during the first year after transplantation did 
not differ between both groups (CsA: mean, 0.83
[range 0 to 4]; Aza-Pred: 0.65 [0 to 3]), nor did the 
number of patients who received a methylpred- 
nisolone cotirse (CsA, N  = 9; Aza-Pred, N = 11). The 
cumulative dose of Pred was higher in the Aza-Pred 
group (5,747 ± 845 versus 4,169 ± 1910 mg; P <
0 .0 0 1 ).
Multiple linear regression was performed to assess 
the independent effects of immunosuppressive treat­
ment and other clinical variables on lipid and (apo)li­
poprotein levels at 1 yr after transplantation. Because 
a number of patients did not keep to their originally 
assigned treatment, the actual use of CsA and of Pred 
(0 if the patient did not take the drug and 1 if he/she 
did) instead of group membership formed explanatory 
variables. Other independent variables were: age, sex 
(0 = male, 1 = female), body m ass index, creatinine 
clearance, proteinuria (0 = absent, 1 = present), 
cumulative doses of corticosteroids (arbitrarily de­
fined as the cumulative dose of Pred plus 0.1 times the 
cumulative dose of methylprednisolone), and use of 
¡3-blockers and calcium antagonists. Table 4 gives
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TABLE 4. Results of multiple linear regression analysis of data  obtained at 1 yr after transplantation0
Dependent Variable Predictor Variable
Partial
Regression
Coefficient13
P
Serum cholesterol Sex (female = 1) 0.86 0.022
Use of caicium-antagonist 0.79 0.044
Age (yr) 0.026 0.049
Serum TG Use of calcium antagonist 0.53 0.043
VLDL cholesterol Creatinine clearance (mL/min) -0.009 0.048
LDL-C
HDL-C Sex (female = 1) 0.35 <0.001
Body mass index (kg /m 2) -0.028 0.002
Use of Pred 0.23 0.046
Creatinine clearance (mL/min) 0.0045 0.046
Age (yr) 0.0058 0.032
apo A-I Sex (female = 1) 282 <0.001
Use of CsA 178 0.019
Use of Pred 181 0.044
Use of calcium antagonist 163 0.008
Body mass index (kg /m 2) -1 3 0.047
apo B
Log (Lp(a)) Use of CsA 0.86 0.036
a Only the variables that showed a significant, independent correlation with a particular Hpld outcome are shown,
bThe regression coefficient shows the expected change In the dependent variable each time the predictor variable Increases by 1 U, holding the 
values of the other predictor variables constant,
those explanatory variables that showed an indepen­
dent association with the respective lipid outcome 
variables. The use of Pred retained a significant rela­
tionship with HDL-C and apo A-1, whereas the use of 
CsA was an independent predictor of (log-normalized) 
Lp(a) and apo A-I. Somewhat surprisingly, the use of a 
calcium antagonist (nifedipine) was independently 
correlated with serum cholesterol, serum TG, and apo 
A-I.
Additional information on the individual effects of 
CsA and Pred on serum lipid and lipoprotein levels 
was obtained in patients who received steroid courses 
for acute rejection. In seven patients who were treated 
with high doses of Pred for acute rejection after prior 
steroid withdrawal, blood samples were obtained b e­
fore and within 3 months after restarting treatment 
with Pred. The effects on serum lipid patterns are 
shown in Figure la . The cessation of Pred at 3 months 
after transplantation was followed by a decrease in 
HDL-C and an increase in TG, resembling the results 
mentioned above. The steroid course was accompa­
nied by a reversion of HDL-C and TG levels to values 
observed during previous Pred treatment. In contrast, 
the treatment of acute rejection with ATG in patients 
on CsA monotherapy was not followed by comparable 
changes (Figure lb). In 10 of the 23 patients who were 
switched to the other treatment group, the blood 
sampling schedule allowed the evaluation of the 
changes in the serum lipid profile after conversion 
from CsA monotherapy to Aza-Pred treatment or vice 
versa (Table 5). The decrease in HDL-C and the rise in 
TG characteristic of steroid withdrawal disappeared 
after the cessation of CsA and the reinstitution of Pred
in all cases. In addition, the data presented in Table 4 
suggest that both treatment regimens have opposite 
effects on the levels of LDL-C.
Our trial was not designed to measure parameters 
of atherosclerosis in depth, but of both patients who 
died, one patient died from an acute myocardial in­
farction (Aza-Pred) and the other died from Pneumo­
cystis carinti pneumonia (CsA). None of the remaining 
patients developed clinical signs of cardiovascular 
disease during the first year after transplantation.
Continued-on-Therapy Analysis
To investigate the separate effects of maintenance 
doses of CsA and Pred on lipid and (apo)lipoprotein 
levels, as well as the changes in lipid levels after 
steroid withdrawal, we analyzed the data again after 
the exclusion of patients who died or experienced graft 
loss (N = 4), patients who did not strictly adhere to 
their assigned treatment protocol (N = 37), and pa­
tients who were treated with high-dose steroids for 
acute rejection (CsA, N = 6; Aza-Pred, N  = 6). The 
demographic and clinical characteristics of the re­
maining 69 patients were not different from those of 
the whole study population given in Table 1. The 
course of the concentrations of serum lipids and 
(apo)lipoproteins is shown in Table 6. Differences 
between both groups are more pronounced in this 
subgroup analysis, especially for HDL-C and Lp(a). 
The proportion of patients with a Lp(a) value above 
300 m g/L (generally used as a cut-off point for in­
creased risk) was 36% in the CsA group and 10% in 
the Aza-Pred group (P <  0.01). In the CsA group, the
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Figure 1. Effects on serum lipids and lipoproteins of steroid 
withdrawal and subsequent treatment with steroids or ATG 
for rejection. Mean (±SE) values of serum lipids and lipopro­
teins before the withdrawal of Pred at 3 months after renal 
transplantation (Tx), after cessation of Pred, and either after 
treatment with high doses of Pred for acute rejection in seven 
patients (a ) or after treatment with ATG for acute rejection in 
five patients (b). Data are presented as percentages with an 
index value of 100% for fhe first lanes. TC, serum total 
cholesterol; * P < 0.05 for differences with values at 3 months 
after transplantation.
relative decrease in HDL-C after steroid withdrawal 
was larger than the accompanying decrease in apo 
A-I, resulting in a significant reduction in the HDL-C- 
to-apo A-I ratio.
DISCUSSION
This study demonstrates that CsA monotherapy 
and Aza-Pred treatment markedly differ in their effects 
on serum lipid and (apo)lipoprotein levels during the
TABLE 5. Direction of changes in serum lipids and  
lipoproteins after conversion from CsA monotherapy 
to Aza-Pred or vice versa
Parameter Increase/decrease
CsA —> 
Aza-Pred 
(N = 5)
Aza-Pred 
CsA 
(N = 5 )
Total cholesterol m 1/4 2/3
LDL-C t / i 1/4 4/1
HDL-C T/4 5/0 2/3
TG m 0/5 3/2
first year after renal transplantation. Because the 
influence of Aza on serum lipid levels has not been 
demonstrated (22), the design of our study allowed a 
direct comparison of the effects of CsA and Pred on 
lipid metabolism. During the first 3 months after 
transplantation, all patients received both CsA and 
Pred, which was followed by the cessation of either 
drug. Concentrations of total cholesterol and LDL-C 
remained elevated in both groups and were compara­
ble to those reported earlier in posttransplant patients 
on various immunosuppressive regimens (12,13). 
However, significant differences between both groups 
were noted for HDL-C, serum TG, and Lp(a). Differ­
ences in HDL-C or TG were not observed in previous, 
relatively small studies comparing the effects of CsA 
monotherapy and Aza-Pred treatment on lipid metab­
olism (9,10),
Diabetic patients were excluded from this study 
because preexisting secondary hypertriglyceridemia 
as well as the influence of Pred on already disturbed 
glucose metabolism would hamper the interpretation 
of the data obtained in these patients. The results may 
therefore not apply to diabetics, who represent a 
substantial part of the renal transplant recipients in 
some countries.
One of our most striking findings was the consider­
able decrease in HDL-C concentration, especially in 
CsA-treated patients. The fall in HDL-C may in part 
have been secondary to the rise in serum TG, but in 
the Aza-Pred group, both HDL-C and TG appeared to 
decrease, which suggests that other mechanisms are 
involved. In general, low HDL-C levels can result from 
a decreased hepatic synthesis or from an increased 
removal from the circulation. The urinary loss of HDL 
has been suggested to occur in patients with the 
nephrotic syndrome (23). It is, however, not a likely 
cause of low HDL levels in our patients because there 
were only a few patients with proteinuria and there 
was no correlation between the degree of proteinuria 
and HDL levels. The time course of the alterations in 
HDL-C and serum TG on CsA monotherapy, with the 
most dramatic changes between 3 and 5 months after 
transplantation, suggests a relation with the cessa­
tion of Pred during exactly the same period. This was 
supported by the normalization of reduced HDL and 
increased TG levels in patients treated with steroid 
courses for acute rejection after prior steroid with-
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TABLE 6. Continued-on-therapy analysis of lipid and (apo)lipoprotein concentrations at 3, 6, and 12 months 
after renal transplantation in patients treated with CsA m onotherapy (/V = 28) or with Aza-Pred (N =  41)
Parameter
CsA Aza-Pred
3 months 6 months 12 months 3 months 6 months 12 months
Serum cholesterol (mmoi/L) 6.16 ± 1.53 5.90 ±  1.06 5.85 ±  1.17 6.26 ±  1.37 5.84 ±  1.21 5.86 ±  1,17°
Serum TG (mmol/L) 1.70 ± 0.84 2.54 ±  1.57b 2.19 ±  1.18° 2.10 ±  0.97 1.81 ±  0.86 1.76 ±  0.83e
LDL-C (mmol/L) 4.20 ± 1.32 3.93 ±  0.80 3.94 ±  1.01 4.06 ±  1.12 3.99 ±  1.17 3.96 ±  1.02
HDL-C (mmol/L) 1.35 ± 0.36 0.90 ±  0.25b 0.99 ±  0.36b 1.32 ±  0.45 1,16 ±  0.44a,d 1.16 ±  0.39
Totai/HDL-C 4.86 ±  1.53 7.00 ±  2.24b 6.77 ± 2.87b 5.17 ±  1.89 5.47 ±  ].64c,d 5.49 ±  1.96*
apo A-I (mg/L) 1,568 ± 2 7 7 1,316 ±  247b 1,383 ± 2 5 1 c 1,510 ± 2 7 5 1,437 ± 3 0 2 1,388 ±  237a
HDL-C/apo A-I (mmol/g) 0.85 ±0.17 0.68 ± 0.13b 0.70 ± 0. Ì7C 0.88 ±  0.18 0.81 ±  0.18c,d 0.82 ±  0.18d
apo B (mg/L) 1,313 ±  389 1,236 ±  241 1,288 ±297 1,257 ±  327 1,251 ±  269 1,218 ±  282
Lp(a) (mg/L)f 84 (38-378) 166 (71-479)° 72 (25-277) 38 (21-176)d
a P < 0.05 for difference versus 3 months. 
b P < 0.001 for difference versus 3 months. 
c P < 0.0] for difference versus 3 months. 
d P < 0,01 for difference with CsA group. 
e P < 0.05 for difference with CsA group, 
f Given as median with Interquartile range.
drawal (Figure 1). The lack of a similar response to 
treatment with ATG argues against a role of the devel­
oping or resolving rejection process itself in the pro­
duction of these changes. Comparable observations 
on the effects of the reinstitution of Pred after previous 
steroid withdrawal were made in patients who 
switched from CsA monotherapy to Aza-Pred treat­
ment. Finally, multiple linear regression analysis re­
vealed that the use of Pred was an independent pre­
dictor of HDL-C and of the major protein component of 
HDL, apo A-I, at 1 yr after transplantation.
The literature lacks agreement on HDL-C levels after 
renal transplantation, but increased HDL levels have 
been reported more than once in earlier years when 
immunosuppressive regimens without CsA contained 
higher Pred dosages (24). An effect of steroids on 
HDL-C is supported by a previously noted decrease in 
HDL-C after steroid withdrawal (8) and by the rise in 
HDL-C observed after the short-term administration 
of corticosteroids in healthy men (25,26) or in patients 
with various disorders (27,28). The increase in HDL-C 
was often not accompanied by a significant increase in 
apo A-I, resulting in an increased lipid-to-protein ratio 
in HDL (24,26,27). Our finding of a significantly lower 
ratio of HDL-C to apo A-I in patients who stopped 
taking Pred (CsA group), as compared with those in 
whom the dosage was reduced (Aza-Pred group), is in 
accordance with these observations.
The mechanism by which corticosteroid administra­
tion increases HDL-C levels is not clear. Animal stud­
ies have shown increases in the hepatic production of 
nascent HDL-C after corticosteroid administration 
(29). Furthermore, increased activity of lipoprotein 
lipase during the administration of Pred has been  
associated with a rise in HDL-C and may also contrib­
ute to a decrease in TG (25,26). Alternatively, de­
creased activity of hepatic lipase, enhanced activity of 
lecithin-cholesterol acyltransferase (24), or changes in
cholesteryl ester transport could be involved. In pa­
tients with nephrotic syndrome, corticosteroid ther­
apy has been associated with a reduction in plasma 
cholesteryl ester transfer protein (CETP) (30). CETP 
mediates the transfer of cholesteryl esters from HDL to 
apo B-containing lipoproteins, and patients with ge­
netic CETP deficiency have increased HDL-C levels 
(31). A reduction in CETP activity by Pred therapy as a 
possible cause of increased HDL-C levels is supported 
by our observation of a significantly smaller choles­
terol content of VLDL in Aza-Pred-treated patients as 
compared with their CsA-treated counterparts.
Taken together, we have strong arguments to a s ­
sume that in our CsA-treated patients, the reduction 
of the Pred dosage from 20 m g/day to 0 contributed to 
the observed fall in HDL-C. The persistence of high 
levels of total cholesterol, LDL-C, and TG is probably 
related to treatment with CsA. In accordance with this 
view, the moderate decrease in HDL-C that occurred 
in the Aza-Pred group may be caused by the reduction 
of the Pred dosage from 20 to 10 m g/day. The ten­
dency for decreases in total cholesterol and TG in  
these patients is in line with the observations in 
previous conversion studies (32,33) and may be at­
tributed to either the discontinuation of CsA or again 
to the reduction of the Pred dosage.
The remarkable increase in Lp(a) levels in CsA- 
treated patients, but not in Aza-Pred-treated patients, 
is in keeping with the results of several recent studies 
(4,34), although opposite data have been reported too 
(35). Multiple linear regression analysis showed an  
independent relationship between the use of CsA and 
(log normalized) Lp(a). The m echanism  by which CsA 
increases the concentration of Lp(a) is unknown. Lp(a) 
levels were demonstrated to be related to the geneti­
cally determined apo(a) phenotype (36). Although 
apo(a) phenotyping was not performed in our study, 
the results indicate that in renal transplant patients,
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Lp(a) levels are not only a function of the phenotype 
but also of the immunosuppressive treatment regimen 
that is used. A recent study showed decreases in Lp(a) 
levels during treatment with glucocorticoids in pa­
tients with rheumatic diseases (28), but the use of 
Pred appeared not to be an independent predictor of 
Lp(a) levels in our multivariate analysis.
What is the clinical significance of our findings? 
Atherosclerosis is a common problem in renal trans­
plant recipients, with coronary heart disease being the 
main cause of death in this population (37). Hyperlip- 
idemia plays an important role in the pathogenesis of 
atherosclerosis, and from large epidemiologic studies, 
it is known that low HDL-C levels, as well as high total 
cholesterol and LDL-C levels, are independent risk 
factors for coronary heart disease (15,38,39). Hyper­
triglyceridemia has been found to be an independent 
risk factor in some studies (40). Kasiske demonstrated 
an independent association between serum choles­
terol and ischemic heart disease in a large population 
of renal transplant recipients (41). Regarding the mag­
nitude of the effect of a decrease in HDL-C, it was 
estimated from the Framingham Heart Study that a 
decrease of 10 mg/dL (0.26 mmol/L) was associated 
with an increase in the risk for mortality due to 
coronary heart disease of 18,9 and 28.1% for men and 
women, respectively (39). Similarly, in the Physician’s 
Health Study, a change of 1 U in the ratio of total 
cholesterol to HDL-C, like the difference between the 
means of our study groups at 1 yr after transplanta­
tion, was associated with a 53% change in the risk of 
myocardial infarction (15). Despite these persuasive 
figures for the general population, we have to be 
cautious in concluding that a decrease in HDL-C after 
steroid withdrawal will equally worsen the cardiovas­
cular risk in renal transplant patients. If steroids 
would alter the composition of HDL in a nonbeneficiai 
way, the improved composition of HDL after steroid 
withdrawal could outweigh the potentially negative 
effects of lower HDL-C levels. However, the rise in the 
lipid-to-protein ratio of HDL, as well as previously 
observed increases in the HDL2 subfraction (26,42), 
points to favorable changes in the composition of HDL 
after the administration of Pred (15). Lp(a) is not only 
positively associated with coronary heart disease but 
may also have detrimental effects on hemostasis and 
thrombosis (16).
In conclusion, the resulting lower HDL-C, higher 
serum TG, and higher Lp(a) levels suggest that CsA 
monotherapy is a less attractive immunosuppressive 
treatment strategy than Aza-Pred treatment in terms 
of risk for coronary heart disease. Moreover, the 
changes in HDL-C and TG that we observed after the 
cessation and resumption of Pred in CsA-treated pa­
tients indicate that the widespread assumption that 
steroid withdrawal improves the serum lipid pattern 
after renal transplantation may be false. In this re­
gard, Pred may even exert some protective effect in 
CsA-treated patients. Currently, we are performing a 
prospective study to compare the effects of CsA-Aza
treatment with that of CsA-Pred treatment on serum
lipids and lipoproteins.
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